Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Advisory Board

Ian J. Constable, M.D.

Dr. Constable is Founder and Professor of Ophthalmology at the Lions Eye Institute, University of Western Australia, and is an expert in gene therapy approaches to retinal disease.

Mark S. Blumenkranz, M.D.

Dr. Blumenkranz is Professor and Chairman at the Byers Eye Institute at Stanford. He is a renowned expert in retinal disease and has founded several Silicon Valley startup companies.

Steven D. Schwartz, M.D.

Dr. Schwartz is Professor of Ophthalmology and Chief of Retina Division at the UCLA Jules Stein Eye Institute. He is a renowned expert in retinal diseases and early-stage clinical research.

Judy Gordon, D.V.M.

Dr. Gordon is a Clinical Regulatory Consultant with extensive experience in Ophthalmology products.

Steven Butler, Ph.D.

Dr. Butler is a Consulting Biostatistician. As an Associate Director at Genentech, he served as the lead biostatistician and development sub-team leader for Lucentis.

Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO

MENLO PARK, Calif., Nov. 20, 2015 -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm. Subsequent to December 9, Hans P. Hull who has been serving as interim CEO of Avalanche since July, will return to his previous role of senior vice president of business operations.

Read More

Read All Avalanche News